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Objective: Regarding vulvar cancer, a nomogram has been suggested for the prediction of relapse-free survival (RFS). 
While the nomogram has been developed and validated in a Western study, there was no validation in Korean 
population. Thus, we have undertaken the study to assess the applicability of nomogram for predicting RFS in Korean 
patients with vulvar cancer.
Methods: A total of 204 cases newly diagnosed as vulvar cancer between 1982 and 2006 were identified. Among them 
70 cases were not eligible due to inappropriate cell type (40 cases) and radiation as primary therapy (30 cases). Forty- 
four cases were not evaluable due to inadequate data and persistent disease. Finally a total of 90 patients primarily 
treated by surgery were included for analysis. Variables including age and the characteristics of primary tumor, nodal 
status, and surgical margin were collected for predicting RFS based on nomogram, which was compared with actual 
RFS. A calibration plot was drawn showing the actual versus predicted probability for 6 groups of patients segregated 
according to their predicted probabilities. In addition, discrimination of the nomogram was quantified with the 
concordance index.
Results: Patients’ mean age was 58 years and mean follow-up period was 47.9 months. Observed 2y- and 5y-RFS rates 
were 81% and 68%, respectively, corresponding to 79% and 72% in the original cohort. The trend line in calibration 
plot showed comparable concordance with an ideal line, having a slope of 1.04 for 2y-RFS (R2=.35) and 0.98 for 
5y-RFS (R2=.80), respectively. The concordance index was 0.79 in the KGOG data set, which was improved to 0.82 
with the data set limited to squamous cell carcinoma.
Conclusion: The nomogram provides the predictive capacity for relapse-free survival in Korean patients with vulvar 
cancer.
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INTRODUCTION
  Vulvar cancer accounts for 3-5% of all gynecological malig-
nancies.1,2 During recent years, it appears that this incidence 
has been increasing along with the rise in the average age of 
the female population.
  Significant advances in the management of vulvar cancer 
have led to decrease in physical and psychological morbidity 
associated with the treatment. This improvement was en-
abled by better understanding of the prognosis or course of 
the disease. Furthermore, if we can predict the individual risk 
of recurrence, we will be able to adjust the therapeutic modal-
ities to decrease the incidence of recurrence as well as to de-
crease morbidity.
  One such predictive tool is the nomogram, which is a stat-
istical tool that enables users to calculate the overall proba-
bility of a specific outcome.3 Several studies in various can-
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Patient characteristics
Original cohort (n=244)
n (%)
KGOG cohort (n=90)
n (%)
p
Mean age (years, range)
T stage
  1
  2
  3/4
Pathologic LN status
  Negative
  Positive
FIGO stage
  I
  II
  III
  IV
Unknown
Margin status
  Negative (＞3 mm)
  Positive (≤3 mm)
    69 (24–96)
112 (45.9)
110 (45.1)
22 (9.0)
189 (77.5)
  55 (22.5)
  91 (37.3)
  52 (21.3)
  59 (24.2)
18 (7.4)
24 (9.8)
204 (83.6)
  40 (16.4)
58.2 (26–78)
39 (43.3)
45 (50.0)
6 (6.7)
74 (82.2)
16 (17.8)
35 (38.9)
34 (37.8)
14 (15.6)
7 (7.8)
  56 (62.2)
  34 (37.8)
.647
.370
.043
＜.001
Table 1. Descriptive Satistics for Vulvar Cancer Patient Cohorts from Centre Hospitalier Intercommunal de Creteil (Original cohort) and 
Korean Gynecologic Oncology Group (KGOG)
cers, such as sarcoma, prostate, and breast cancer, suggested 
improved predictive accuracy for the nomogram, compared to 
the conventional prognostic groupings.4-6
  In 2006, Rouzier and co-workers suggested a nomogram for 
prediction of the risk of recurrence in vulvar cancer patients.7 
In the nomogram, seven variates which were thought to be re-
lated to relapse-free survival were included to calculate the 
probability of relapse-free survival at 2 and 5 years as a percen-
tage. These seven variates were age, tumor (T) stage, number 
of metastatic nodes, bilateral node involvement, omission of 
lymphadenectomy, margin status, and depth of invasion. 
They advocated that their nomogram predicted survivals bet-
ter than did the International Federation of Gynecology and 
Obstetrics (FIGO) stage.
  The aim of this study was to evaluate the predictive accuracy 
of the vulvar cancer nomogram in a different ethnic group, 
and, as a consequence, to assess the generalizability of the 
nomogram. Thus, we validated the nomogram in a cohort of 
vulvar cancer patients treated in Korea. 
MATERIALS AND METHODS
  Between October 1982 and September 2006, 204 consec-
utive patients were diagnosed with vulvar cancer in 11 in-
stitutions constituting the Korean Gynecologic Oncology 
Group (KGOG). All medical records were retrospectively re-
viewed, including pathology reports, operation records, and 
follow-up data. The data from each institution were collected 
by a single institution utilizing clinical report forms (CRF). 
Items on CRF included seven variables of the vulvar cancer 
nomogram, including age, tumor (T) stage, number of meta-
static nodes, bilateral node involvement, omission of lympha-
denectomy, margin status, and depth of invasion.
  Forty patients with histologic types melanoma and Paget’s 
disease were excluded from the analysis due to their markedly 
different clinical behavior and prognosis. In addition, 44 cases 
which were not evaluable due to inadequate data and persistent 
diseases and 30 cases in which radiation was the primary ther-
apy were excluded, leaving 90 patients with all nomogram vari-
ables, FIGO stage, adequate histologic types, and follow-up 
data. 
  Relapse-free survival (RFS) was defined as the time from sur-
gery to relapse or last follow-up. Nomogram validation com-
prised two activities; discrimination and calibration. First, dis-
crimination was quantified with the concordance index, which 
is similar to the area under the receiver operating characteristic 
curve. The concordance index provides the probability that the 
nomogram will predict a poorer outcome for the patient who 
relapses first out of a randomly selected pair of patients. 
Second, calibration was assessed. Calibration compares the 
predicted probability of relapse-free survival with the actual 
survival. This was performed by grouping patients with respect 
to their nomogram-predicted probabilities for relapses and 
then comparing the mean of the group with the observed 
Kaplan-Meier relapse-free survival estimate. All analyses were 
conducted using SPSS 13.0 (SPSS Inc., Chicago, IL). 
RESULTS
  Descriptive statistics for the KGOG data set are summarized 
and compared with those for the original-development data 
set in Table 1. One of the main differences between the two 
cohorts was a higher rate of positive resection margin, defined 
as 3 mm or less, in the KGOG cohort (p＜.001). In addition, 
a slightly higher percentage of patients in the KGOG cohort 
were diagnosed with earlier stages (p=.043). 
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Fig. 1. A receiver operating characteristic (ROC) curve assessing the discrimination of the nomogram. A concordance indexes (CI) in (A) the 
entire KGOG data set (n=90) and (B) the squamous cell carcinoma data set were 0.794 and 0.823, respectively.
Fig. 2. Calibration of the vulvar cancer nomogram with the KGOG data set. Nomogram was applied to the KGOG data set (A) at 2 years and 
(B) at 5 years.
  With mean follow-up period of 47.9 months (range, 1 to 
269.7 months), the 2-year and 5-year relapse-free survival 
rates in the KGOG cohort were 81% and 68%, respectively, 
corresponding to 79% and 72% in the original cohort. 
  The nomogram concordance index (CI) in the KGOG data 
set was 0.79. When the application was limited to the 82 pa-
tients with squamous cell carcinoma, the concordance index 
improved to 0.82 (Fig. 1). This was similar to the CI of the 
original cohort (CI=0.83), and also superior to the CI of the 
FIGO staging system (CI=0.78). 
  To assess the calibration of the nomogram, actual proba-
bilites were plotted against the calculated predicted proba-
bilities for each group of patients (Fig. 2). Patients were group-
ed according to their nomogram-predicted probabilities for re-
lapses into 6 groups. The trend line in calibration plot showed 
comparable concordance with an ideal line, having a slope of 
1.04 for 2-year RFS (R2=.35) and 0.98 for 5-year RFS 
(R2=.80), respectively.  
DISCUSSION
  Radical vulvectomy and en bloc groin dissection, with or 
without pelvic lymphadenectomy was the mainstay of treat-
ment in vulvar cancer. However, due to the high incidence of 
postoperative morbidities, including physical and psycho-
logical morbidity, a number of attempts have been made to 
provide conservative therapy on an individual basis with mini-
mal risk of recurrence. These advances were enabled by better 
understanding of the prognosis or course of the disease.8-11
  The conventional prognostic tool is FIGO staging system.12 
This system is based on tumor size, lymph node status, and 
presence of distant metastasis. On the whole, the prognosis 
correlates with the FIGO stage. However, there are some 
limitations. One major problem is that stage III represents a 
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very heterogeneous group of patients. Despite being the same 
stage, involvement of the inguinal lymph nodes in FIGO stage 
III patients carries a significantly worse prognosis compared 
with invasion of the lower urethra, vagina or anus alone.13 In 
addition, FIGO stage does not fully reflect some important 
prognostic factors. These include the number of positive in-
guinal-femoral lymph nodes14, omission of lymphadenec-
tomy, and margin status.10
  Therefore, a nomogram, which incorporates more clinical 
and pathologic factors than the staging system, can allow the 
clinician to achieve a better estimation of the prognosis of an 
individual patient. Another potential benefit of nomogram is 
that it creates a simple graphical representation of a statistical 
predictive model that generates a numerical probability of a 
clinical event. But, one should be cautious about extrapolat-
ing from regression models built on different populations.15 
Because a nomogram derived from one population may not be 
applicable to a new population, external validation is man-
datory. The vulvar cancer nomogram was built and validated 
in a white population. Although found to be accurate by in-
ternal and external validation methods, this nomogram had 
not been validated in a different ethnic group. Therefore, the 
current study assessed the generalizability of the nomogram 
in a Korean population. 
  The clinicopathologic variables in the two cohorts were sim-
ilar, except for FIGO stage and resection margin status. The 
differences, in addition to race effect, enabled the validation to 
be operated in a separate cohort. 
  In this study, a comparable concordance index and a sim-
ilarly good calibration plot were obtained when the vulvar 
cancer nomogram was applied to the Korean population. 
When the data set was limited to squamous cell carcinoma, 
the concordance index improved from 0.79 to 0.82, indicating 
that the nomogram might be more predictive for patients with 
squamous cell carcinoma of vulva. In addition, the calibration 
of the nomogram for the 5-year RFS was better than that for 
2-year RFS. 
  There are some limitations to our study. First, the number of 
patients included in this study was small, despite of the mul-
ti-institutional study. But, this limitation is inherent to rarely 
occurring cancer such as vulvar cancer. Second, the study design 
was retrospective. Since the clinicopathologic data were col-
lected retrospectively from different institutions, the data 
might not be uniform. But, this limitation did not affect the 
study analysis because the aim of this study was to assess the 
generalizability of the nomogram. However, prospective ran-
domized trials, incorporating the nomogram in stratification 
of patients, are still warranted to evaluate the role of nomogram.
  In conclusion, the current study confirmed that the vulvar 
cancer nomogram is a valuable tool for individual prognostic 
assessment. The resulting risk estimates can help clinicians to 
counsel patients on an individual basis and to provide more 
tailored adjuvant therapy.
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